Aim: To evaluate the efficacy of different variants of immunotherapy, namely, adoptive LAK-therapy, vaccine therapy and their combination in vivo using transplantable murine MC-rhabdomyosarcoma resistant and sensitive to doxorubicin (Dox). Materials and Methods: The study was carried out on BALB/c mi...
Identifying different ways to stimulate the anti-tumor immune response is essential to enrich the immunotherapy arsenal with more and improved treatment options for patients.Despite the fact that immuno-oncology has become one of the leading areas in cancer research in recent years, the arsenal of ...
Current cancer treatment offers more options than before, including not just chemotherapy and radiotherapy but also immunotherapy, such as immune checkpoint inhibitors (ICIs). Due to their efficiency and relatively less severe adverse effects compared to certain chemotherapies, ICIs are now approved for...
Although inflammation takes part in the initiation and perpetuation of AF, the efficacy of anti-inflammatory treatment in the clinic is far from satisfactory. Like the varied efficacy of immunotherapy for different immunophenotypes in tumors, we speculated that there is varied efficacy of anti-...
A dichotomy between immunologically active and quiescent cancer phenotypes has been demonstrated for several types of cancer. Central to such dichotomy is ... D Murtas,D Maric,VD Giorgi… - 《Journal for Immunotherapy of Cancer》 被引量: 0发表: 2013年 Increased Immune Reactivity Predicts Aggressive...
Immunotherapy—A therapy that boosts your body’s own immune system to fight cancer. CAR T-cell therapy—A treatment that boosts your immune system’s cells (specifically cells known as T-cells) to help fight cancer. This process involves removing T-cells from your body, training them to rec...
Vaccine therapy of B cell malignancies: different strategies for a novel approach. This review deals with the theoretical principles and experimental results of immunotherapy for B cell malignancies, namely for non-Hodgkin lymphomas (NHLs... A Liso,R Benedetti,L Flenghi,... - 《Leukemia & Lymph...
In addition to deciphering the tumor cells, efforts have been made to characterize the tumor immune microenvironment (TIME), improving the clinical benefit of immunotherapy, especially anti-PD-1/L1 and anti-CTLA4 antibodies [10, 11]; however, many patients still have poor outcomes [12, 13]. ...
Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43(3): 321–332. https://doi.org/10.1016/j.neuron.2004.07.003 54. Price JL, Davis PB, Morris ...
Enhancing Outcomes With Immunotherapy Agents for Patients With Non-Muscle Invasive Bladder Cancer Alexandra Gerlach, Associate Editor February 1st 2025 The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma Alexandra Gerlach, Associate Editor Published: February 15th 2025 | Updated...